Clinical Trials | December 03, 2025
Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
This is the group’s first NoC approval in Canada
Subscribe To Our Newsletter & Stay Updated
